MX2018009011A - Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. - Google Patents
Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.Info
- Publication number
- MX2018009011A MX2018009011A MX2018009011A MX2018009011A MX2018009011A MX 2018009011 A MX2018009011 A MX 2018009011A MX 2018009011 A MX2018009011 A MX 2018009011A MX 2018009011 A MX2018009011 A MX 2018009011A MX 2018009011 A MX2018009011 A MX 2018009011A
- Authority
- MX
- Mexico
- Prior art keywords
- ror1
- thyrosine
- transmembrane
- receiver
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290337P | 2016-02-02 | 2016-02-02 | |
| US201662324876P | 2016-04-19 | 2016-04-19 | |
| PCT/US2017/016300 WO2017136607A1 (en) | 2016-02-02 | 2017-02-02 | Anti-ror1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009011A true MX2018009011A (es) | 2018-11-19 |
Family
ID=58054529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009011A MX2018009011A (es) | 2016-02-02 | 2017-02-02 | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10968275B2 (https=) |
| EP (2) | EP4006056A1 (https=) |
| JP (2) | JP7029401B2 (https=) |
| CN (1) | CN108699149B (https=) |
| AU (1) | AU2017213844A1 (https=) |
| CA (1) | CA3012827A1 (https=) |
| ES (1) | ES2903228T3 (https=) |
| MX (1) | MX2018009011A (https=) |
| WO (1) | WO2017136607A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6865688B2 (ja) | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| EA201891066A1 (ru) | 2015-10-30 | 2018-10-31 | ЭнБиИ-ТЕРАПЬЮТИКС АГ | Антитела к ror1 |
| SG11201806120WA (en) | 2016-01-20 | 2018-08-30 | Scripps Research Inst | Ror1 antibody compositions and related methods |
| CN108699149B (zh) | 2016-02-02 | 2023-01-06 | 弗雷德哈钦森癌症中心 | 抗-ror1抗体及其用途 |
| IL268349B2 (en) | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| EP3665193A1 (en) | 2017-08-07 | 2020-06-17 | NBE Therapeutics AG | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| JP7447006B2 (ja) | 2017-11-01 | 2024-03-11 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体 |
| SG11202003427XA (en) | 2017-11-06 | 2020-05-28 | Juno Therapeutics Inc | Combination of a cell therapy and a gamma secretase inhibitor |
| GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2020143506A1 (zh) * | 2019-01-08 | 2020-07-16 | 深圳大学 | 检测多种恶性肿瘤细胞的抗体及其应用 |
| CA3123303A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| WO2023186100A1 (zh) * | 2022-04-02 | 2023-10-05 | 山东先声生物制药有限公司 | 抗ror1的抗体及其用途 |
| IL318546A (en) * | 2022-07-26 | 2025-03-01 | Aimed Bio Inc | Anti-ROR1 antibody and its uses |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物（武汉）科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024140641A1 (zh) * | 2022-12-27 | 2024-07-04 | 上海医药集团生物治疗技术有限公司 | 靶向ror1的抗原结合蛋白 |
| CN115894691B (zh) * | 2022-12-27 | 2026-03-03 | 上海医药集团生物治疗技术有限公司 | 靶向ror1的抗原结合蛋白 |
| CN116183472B (zh) * | 2023-04-25 | 2023-08-18 | 上海益诺思生物技术股份有限公司 | Cba法检测非人类灵长类动物细胞因子的验证方法 |
| WO2025007910A1 (en) * | 2023-07-04 | 2025-01-09 | TJ Biopharma (Shanghai) Co., Ltd. | Anti-ror1 antibodies and uses thereof |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA114536A (en) | 1908-09-18 | 1908-10-13 | Adolphe Chalas | Nickel recovering process |
| CA138293A (en) | 1911-11-06 | 1912-02-06 | Charles E. Archie | Variable speed gearing |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| CA2480052A1 (en) | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| WO2005035732A2 (en) | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
| WO2005037235A2 (en) | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| US7973139B2 (en) | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| BRPI0910509B8 (pt) | 2008-07-10 | 2021-05-25 | Toray Industries | uso do anticorpo, anticorpo e composição farmacêutica |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| WO2010124188A1 (en) | 2009-04-23 | 2010-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| US9163258B2 (en) | 2010-07-23 | 2015-10-20 | Fred Hutchinson Cancer Research Center | Method for the treatment of obesity |
| EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| US9758586B2 (en) | 2010-12-01 | 2017-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| AU2012294431B2 (en) | 2011-08-09 | 2017-03-30 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (PC) and/or PC conjugates |
| SG11201400859SA (en) | 2011-09-22 | 2014-04-28 | Amgen Inc | Cd27l antigen binding proteins |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| EP2968601A1 (en) | 2013-03-10 | 2016-01-20 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| KR102048855B1 (ko) | 2014-07-29 | 2019-11-26 | 셀렉티스 | 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체 |
| MX389823B (es) | 2014-10-27 | 2025-03-20 | Fred Hutchinson Cancer Center | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
| JP6865688B2 (ja) | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| CN108137669B (zh) | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
| CN108699149B (zh) | 2016-02-02 | 2023-01-06 | 弗雷德哈钦森癌症中心 | 抗-ror1抗体及其用途 |
| MA45341A (fr) | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
-
2017
- 2017-02-02 CN CN201780009313.5A patent/CN108699149B/zh active Active
- 2017-02-02 US US16/074,737 patent/US10968275B2/en active Active
- 2017-02-02 JP JP2018539977A patent/JP7029401B2/ja active Active
- 2017-02-02 EP EP21204990.2A patent/EP4006056A1/en active Pending
- 2017-02-02 MX MX2018009011A patent/MX2018009011A/es unknown
- 2017-02-02 WO PCT/US2017/016300 patent/WO2017136607A1/en not_active Ceased
- 2017-02-02 CA CA3012827A patent/CA3012827A1/en active Pending
- 2017-02-02 ES ES17705745T patent/ES2903228T3/es active Active
- 2017-02-02 EP EP17705745.2A patent/EP3411408B1/en active Active
- 2017-02-02 AU AU2017213844A patent/AU2017213844A1/en not_active Abandoned
-
2021
- 2021-01-25 US US17/157,810 patent/US11932691B2/en active Active
- 2021-12-02 JP JP2021196080A patent/JP2022028918A/ja active Pending
-
2024
- 2024-02-07 US US18/435,933 patent/US20240352119A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108699149A (zh) | 2018-10-23 |
| WO2017136607A1 (en) | 2017-08-10 |
| US20210147540A1 (en) | 2021-05-20 |
| CN108699149B (zh) | 2023-01-06 |
| JP2022028918A (ja) | 2022-02-16 |
| EP4006056A1 (en) | 2022-06-01 |
| US11932691B2 (en) | 2024-03-19 |
| US20240352119A1 (en) | 2024-10-24 |
| AU2017213844A1 (en) | 2018-08-02 |
| EP3411408B1 (en) | 2021-12-08 |
| ES2903228T3 (es) | 2022-03-31 |
| JP7029401B2 (ja) | 2022-03-03 |
| EP3411408A1 (en) | 2018-12-12 |
| US10968275B2 (en) | 2021-04-06 |
| CA3012827A1 (en) | 2017-08-10 |
| US20190040132A1 (en) | 2019-02-07 |
| JP2019511904A (ja) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
| CL2019003000A1 (es) | Proteínas de unión a antígenos trem2 y usos de estas. | |
| ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| MX2024001803A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| CO2017012974A2 (es) | Anticuerpos de unión a tau | |
| MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| ECSP21010450A (es) | Anticuerpos antisortilina y métodos para su uso | |
| PE20200486A1 (es) | Anticuerpos anti-cd33 y metodos para utilizarlos | |
| CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
| CO2017012971A2 (es) | Anticuerpos de unión a tau | |
| MX2021007768A (es) | Anticuerpos anti-ctla4 y metodos de uso de los mismos. | |
| CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
| BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
| CO2017000571A2 (es) | Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena | |
| CL2017000515A1 (es) | Cd123 agentes enlazadores y su uso | |
| MX2017003268A (es) | Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares. | |
| PE20240111A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
| MX2020013122A (es) | Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47). | |
| MX2016001741A (es) | Diacuerpos fc monovalentes biespecificos que son capaces de unirse a cd32b y cd79b y usos de los mismos. | |
| MX2022011972A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
| EA201992883A1 (ru) | АНТИТЕЛА К TrkB | |
| MX2020003563A (es) | Anticuerpo anti-pacap. | |
| UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso |